Form 8-K - Current report:
SEC Accession No. 0001493152-25-001516
Filing Date
2025-01-10
Accepted
2025-01-10 06:04:59
Documents
17
Period of Report
2025-01-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48590
2 ex1-1.htm EX-1.1 21186
3 ex5-1.htm EX-5.1 17550
4 ex5-1_001.jpg GRAPHIC 2863
  Complete submission text file 0001493152-25-001516.txt   324270

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ptix-20250109.xsd EX-101.SCH 3796
6 XBRL DEFINITION FILE ptix-20250109_def.xml EX-101.DEF 30062
7 XBRL LABEL FILE ptix-20250109_lab.xml EX-101.LAB 36749
8 XBRL PRESENTATION FILE ptix-20250109_pre.xml EX-101.PRE 27085
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5772
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

IRS No.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 25520087
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)